Loading stock data…
ATR
$119.96-1.03 (-0.85%)
Market ClosedLast close May 11
AptarGroup, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AptarGroup, Inc. in the Healthcare sector is trading at $119.96. The stock is currently 27% below its 52-week high of $164.28, remaining 6.8% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ATR maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$119.96
Potential Downside
1.5%
Whystock Fair Value$118.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$163.29+36.1%
Range$145.00 – $220.00
Fundamentals
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and bever...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Strong income play. Yield provides a meaningful total return floor.
149.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.67%
Volume
Today's trading volume
488,437
Recent News
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results. President and Chief Executive Officer Stephan Tanda told shareholders that he p
AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
Earnings Update: AptarGroup, Inc. (NYSE:ATR) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its quarterly result this time last week. The...
AptarGroup Inc (ATR) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational ...
AptarGroup Inc (ATR) reports an 11% sales increase, driven by robust demand in injectables and consumer healthcare, despite margin pressures and segment-specific hurdles.
Assessing AptarGroup (ATR) Valuation After First Quarter Earnings Beat And Profit softness
AptarGroup (ATR) has drawn fresh attention after reporting first quarter 2026 results that topped consensus forecasts for both earnings and revenue, even though net income and earnings per share were lower than a year earlier. See our latest analysis for AptarGroup. Even with the earnings and revenue beat, AptarGroup’s recent share price performance has been weak, with a 30 day share price return decline of 6.1% and a 1 year total shareholder return decline of 20.9%, pointing to fading...